Business
Longeveron Announces 2025 Full Year Financial Results and Provides Business Update
On track for third quarter 2026 top-line trial results from anticipated pivotal Phase 2b clinical trial (ELPIS II) evaluating laromestrocel as a potential
About this update from Longeveron Inc.
[{"type":"text","content":"On track for third quarter 2026 top-line trial results from anticipated pivotal Phase 2b clinical trial (ELPIS II) evaluating laromestrocel as a potential adjunct treatment for HLHS, a rare pediatric disease and orphan-designated indicationELPIS II may serve as foundation for a Biologics License Application (BLA) submission for full approval for HLHS, if results demonstrate sufficient evidence of efficacyClosed a private placement of up to $30 million, with $15 million funded in the initial closing, led by Coastlands Capital with participation from Janus Henderson Investors and other healthcare focused fundsCompany to host conference call and webcast today at 4:30 p.m. ET MIAMI, March 17, 2026 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing cellular therapy for life-threatening, rare pediatric and chronic aging-related conditions, today reported financial results for the year ended December 31, 2025 and provided a business update. “I am excited to have joined Longeveron at a pivotal moment in the Company’s history,” said Stephen H. Willard, Chief Executive Officer of Longeveron. “With a strong foundation in stem cell science and multiple positive clinical trials with our stem cell therapy across several indications, Longeveron is well positioned to be a leader in advancing stem cell treatments for the benefit of patients and their families. We continue to focus on delivering top-line trial results in the third quarter of 2026 for our anticipated pivotal Phase 2b clinical trial evaluating laromestrocel as a potential treatment for HLHS, a rare pediatric congenital heart defect, and we remain on track to do just that. We plan to focus on a robust partnering strategy across our development programs. We believe this strategy can enable us to build on our stem cell scientific acumen, be more efficient in our use of and need for capital, and leverage the greater resources of larger organizations for mutual success. Lastly, I am delighted to welcome what I believe are two of the premier investment funds in the life sciences space, Coastlands Capital and Janus Henderson Investors, as key shareholders. We appreciate their support, investment and shared vision for advancing stem cell science.” Corporate Strategy UpdateLaromestrocel represents a pipeline in a product opportunity that ha...